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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: Gestational diabetes mellitus (GDM) is a risk for the health of both the pregnant
women and her infant. Its unfavorable effects start in utero and continue after birth. It is
known that GDM increases oxidative stress and decreases antioxidant enzyme activities. In this
study we aimed to investigate cord blood mean platelet volume (MPV) and ischemia-modified
albumin (IMA) levels of infants of diabetic mothers (IDM).
Methods: Twenty-nine pregnant women with GDM between 37 and 41 gestational weeks who
gave birth by spontaneous vaginal delivery were enrolled as study participants together with
20 healthy pregnant women as a control group. Weight, length, and head circumference of ba-
bies were measured by the same standard tape immediately after birth. Five milliliters of um-
bilical venous blood were obtained to study MPV and IMA levels.
Results: There was statistically significant difference in levels of MPV (p Z 0.037) and IMA
(p < 0.001) between groups. They increased in IDM compared with their healthy peers.
Conclusion: Evaluation of MPV and IMA together is useful for representing the potential oxida-
tive stress of IDM.
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Table 1 Cord blood mean platelet volume (MPV) and
ischemia modified albumin (IMA) levels of participants.
GDM pregnant
women
Healthy controls p
MPV, fL
Mean  SD
8.11  0.95 7.55  0.72 0.037
IMA, absorbance
unit
Mean  SD
912.20  92.41 715.60  150.35 <0.001
Data are presented as the mean  standard deviation.
GDM Z gestational diabetes mellitus.
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Prevalence of gestational diabetes mellitus (GDM) is
increasing worldwide and it is reported to range from 1% to
14% in the literature.1 Race, increasing age, and obesity are
the risk factors. Early diagnosis and adequate treatment is
important for prevention of complications. While pre-
eclampsia, polyhydramnios, fetal macrosomia, and opera-
tive delivery are complications that are seen in GDM
pregnant women, hypoglycemia, hypocalcemia, hyper-
bilirubinemia, and polycytemia are some of the complica-
tions seen in the infants of diabetic mothers (IDM). Besides
an increment in perinatal mortality, the risk of developing
type II diabetes mellitus in the following 10 years increases
by 20e30%. Obesity and impaired glucose tolerance ratios
increase in the childhood period of IDM.2
Literature about the oxidative stress increasing effect of
GDM and decreased antioxidant enzyme capacity in those
pregnant women is limited.3 Ischemia modified albumin (IMA)
is a biomarker for acute ischemia that is approved by the US
Food and Drug Administration. When exposed to ischemic
conditions, the N-terminus of albumin is damaged, which
makes it unable tobindmetals and capable of beingmeasured
by an albumin cobalt-binding test. Because its levels in the
blood increase within minutes of the onset of ischemia and
return to normal within 6e12 hours, IMA has been implicated
in the detection of acute ischemia prior to necrosis.4e6
Pregnancy generates a stressful condition in the woman that
is related to increased oxidative stress.7 Gugliucci et al
demonstrated a marked difference of IMA levels between
pregnant and nonpregnant women. IMA levels also increase in
normal vaginal delivery.8e10 There is insufficient literature
investigating the correlation between GDM and IMA levels. Ma
et al found that high levels of IMA and blood glucose levels in
GDMpregnantwomen significantly decreased tonormal levels
after 6 weeks of regular treatment. 11
The mean platelet volume (MPV) is a useful marker to
determine platelet morphology. A normal range of cord
blood MPV levels in healthy newborns has been defined.12
Kipper et al12 also revealed the alterations in thrombo-
cyte and IMA level in mature and premature infants. Dia-
betes also changes thrombocyte function and morphology.
Increased MPV is a direct sign of thrombocyte synthesis and
activation. MPV increases as a result of thrombocyte syn-
thesis. Sak et al showed a clear increase in the MPV of GDM
pregnant women compared with the control group.13
To our knowledge, this is the first study to investigate
the cord blood IMA and MPV levels in the same group of
diabetic patients. In our study, our aim is to investigate
these parameters as a sign of oxidative stress in the IDM.
2. Materials and methods
We performed a caseecontrol study from June 2012 to July
2013 at the Departments of Obstetrics and Gynecology and
Pediatrics at C¸anakkale Onsekiz Mart University Faculty of
Medicine. The approval of the ethics committee of our
university was obtained. Every patient included in the study
signed an informed consent form before participating in the
study. We enrolled 29 GDM pregnant women between 37
and 41 gestational weeks who gave birth by spontaneousvaginal delivery together with 20 healthy pregnant women
as a control group. Pregnant women who did not want to
enroll in the study, gave birth by cesarean delivery, those
who had multiple pregnancies, those with chronic diseases
and fetal anomalies, those using chronic medications, and
those who smoked were excluded from the study.
Postpartum 1st minute and 5th minute APGAR scores were
recorded. Babies were weighed without clothes immediately
after birth. The length of the baby and head circumference
were measured using the same standard tape. Five milliliters
of umbilical venous blood were obtained just after delivery
into dry tubes with separating gel. Blood was centrifuged at
800g at 4C for 15 minutes and the separated serum was
immediately analyzed or frozen at 80C until use. Spec-
trophotometric measurements were made in a Beckman DU
640 spectrophotometer (Beckman Coulter Inc, Fullerton, CA,
USA). IMA was measured by the decrease in cobalt 2þ
binding as previously described.4 We introduced minor
modifications in the method to adapt it to a 96-well plate
reader. Briefly, we added 100 mL of patient serum to 25 mL of
a solution of 1 g/L cobalt chloride and a blank for each serum
was prepared similarly; þ25 mL of a 9.0 g/L solution of NaCl.
After agitation and 10 minutes’ incubation at 25C, dithio-
threitol (25 mL of a 1.5 g/L solution) was then added. After
mixing and 2 minutes’ incubation, the absorbance of assay
mixtures was read at 470 nm, zeroing with the individual
blank. IMA values are expressed in absorbance units (AU).
Platelet count and MPV determinations were performed
based on the Coulter Counter model LH (Coulter Electronics,
Hialeah, FL, USA). Data were recorded using the SPSS 15.0
statistical software package (SPSS Inc., Chicago, IL, USA).
Descriptive data are shown as mean  standard deviation.
ManneWhitney U test was applied for comparisons. A p
value < 0.05 was considered significant.3. Results
Table 1 shows the cord blood levels of IMA and MPV in the
IDM and control groups. The serum IMA levels were signifi-
cantly higher in the IDM group compared with the control
group (p < 0.001; Figure 1). The mean IMA value was
912.20  92.41 AU in IDM group and 715.60  150.35 AU in
the control group. There was also a statistically significant
difference between groups in MPV values. The serum MPV
was significantly higher in the IDM group (p Z 0.037;
Figure 2). In the IDM group, the mean serum MPV was
8.11  0.95 fL and in control group it was 7.55  0.72 fL.
Figure 1 Cord blood ischemia-modified albumin (IMA) levels
of infants of diabetic mothers and healthy controls. The dif-
ference is statistically significant (p < 0.001).
Table 2 Characteristics of case and control groups.
Case Control p
Gestational week 39.1  0.9 39.0  1.2 0.838
Length, cm 49.5  1.6 49.7  1.9 0.657
Head circumference, cm 34.5  1.7 34.4  1.34 0.967
Birth weight, g 3164  551 3212  509 0.799
Platelet count  1012 212.5  68.4 221.9  85.4 0.640
Age of mother, y 31.4  5.3 26.8  5.0 0.004
Data are presented as the mean  standard deviation.
MPV and IMA in infants of diabetic mothers 457Table 2 represents the demographic characteristics of
the newborns and pregnant women in both groups. There
was no statistically significant difference between the
clinical characteristics of the groups except in maternal age
(p > 0.05). The difference in maternal age between groups
did not affect the IMA level or MPV.
4. Discussion
We found a significant elevation in the cord blood level of
IMA and MPV in IDM as evidence of danger to health.
Pregnancy generates a hypoxic condition in experimental
models. Antioxidative defensive mechanisms change during
pregnancy. IMA is used to predict hypoxic conditions, so it
may be used in pregnancy to show hypoxemia. Some studies
have reported increased IMA levels dependent on oxidative
stress triggered by pregnancy.8,9Figure 2 Cord blood mean platelet volume (MPV) of infants
of diabetic mothers and healthy controls. The difference is
statistically significant (p Z 0.037).There is evidence that pregnancy is a physiologically
increased stress condition and in complicated pregnancies
IMA levels increase more than normal ones. O¨zdemir et al
found significantly higher levels of IMA in pregnant women
with habitual abortions.14 This finding may suggest that an
abnormally high hypoxic intrauterine environment may be
associated with abnormal placental development that
contributes to early miscarriage. Pregnant women carrying
fetuses with neural tube defects had higher levels of IMA
when compared to normal pregnant women.15 U¨stu¨n et al
found that moderate and severe preeclamptic pregnant
patients had higher IMA levels than healthy pregnant
women and IMA levels positively correlated with the
severity of preeclampsia.16 In that study they also showed
that healthy and preeclamptic pregnant women had higher
IMA levels than nonpregnant women.
GDM is a risk for the health of pregnant women and their
infants. Women with risk factors should be screened and
early diagnosis should be made for prevention of compli-
cations. The best test for the diagnosis is oral glucose
tolerance test; in our study, all the patients were positive
for this test. Oxidative stress had positive correlation with
increased blood glucose levels, protein oxidation and lipid
peroxidase concentration capacity in GDM pregnant
women.17 Ma et al found high levels of IMA in GDM pregnant
women compared with healthy ones and they attributed
this result to high blood glucose levels.11 In our study, we
found higher levels of IMA in cord blood of IDM than the
controls.
GDM is a systemic disease that affects both mother and
fetus.18,19 The platelet count is slightly lower in pregnant
than in nonpregnant women.20 Platelet levels also decrease
while the duration of pregnancy increases.21 Platelet vol-
ume is a marker of platelet activation and function and is
measured using the MPV.18,19 MPV values have been found
to be higher in diabetic patients when compared to normal
controls. When Sharpe and Trinick compared the MPV of
GDM and healthy pregnant women, they found significantly
higher MPV in GDM pregnant women.22 Kharb23 claimed that
low insulin sensitivity is the cause of the oxidative stress
and leads to free radical production. Because GDM mark-
edly triggers oxidative stress and MPV directly shows the
response of the thrombocytes to the stress, MPV may be
used as a marker for oxidative stress.
Patients with diabetes have increased platelet activa-
tion compared to nondiabetic individuals.19,24,25 MPV values
can serve as an effective marker of blood glucose
levels.18,26 Recently, Bozkurt et al19 claimed that GDM pa-
tients had higher MPV values than normal controls and that
patients with high MPV values had low platelet counts. It
458 N. Topaloglu et alhas been reported that platelet survival is shorter in dia-
betic patients.19,26
MPV increment also showed in metabolic syndrome,27
myocardial infarction,28 and stroke29 cases. S‚ahin et al
30
found that severe preeclamptic pregnant women had
higher MPVs than mild preeclamptic and healthy pregnant
women. Large thrombocytes are more active, produce
more prothrombotic factors and adhere easily.31 We did not
find statistically significant difference between the groups
in thrombocyte counts. MPVs are statistically higher in IDM
in our study and this finding is supported by the literature.
In conclusion, evaluation of MPV and IMA is useful for
representing the potential oxidative stress of IDM.
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